FrancophonIA/ELRC3.0 huggingface dataset:
English: If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.
Estonian: VÄLISPAKENDIL VÕI SELLE PUUDUMISEL SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED
English: Retacrit is used in the following situations:
Estonian: Retacriti kasutatakse järgmistel juhtudel:
English: The European Commission granted a marketing authorisation valid throughout the EU for Retacrit on 18 December 2007.
Estonian: Euroopa Komisjon andis Retacriti müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 18. detsembril 2007.
English: The full EPAR for Retacrit can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Retacriti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Retacrit epoetin zeta
Estonian: Retacrit dzeetaepoetiin
English: After that, the two groups switched to receiving the other medicine for a further 12 weeks.
Estonian: Seejärel viidi mõlemad rühmad üle ravile teise ravimiga ja ravi jätkati veel 12 nädalat.
English: The Committee recommended that Retacrit be given marketing authorisation.
Estonian: Komitee soovitas anda Retacriti müügiloa.
English: This means that Retacrit is similar to a biological medicine (the ‘reference medicine') that is already authorised in the European Union (EU), and contains a similar active substance to the reference medicine.
Estonian: See tähendab, et Retacrit on sarnane bioloogilise ravimiga (võrdlusravimiga), millel juba on Euroopa Liidus müügiluba ning mis sisaldab sarnast toimeainet.
English: The dose, the frequency of injection and how long Retacrit is used for depend on why it is being used, and are adjusted according to the patient's response.
Estonian: Annus, süstimissagedus ja kasutamise kestus sõltuvad Retacriti kasutamise põhjusest ning neid kohandatakse patsiendi ravivastuse järgi.
English: In these cases, erythropoietin is used to replace the missing hormone or to increase red blood cell counts.
Estonian: Sellistel juhtudel kasutatakse erütropoetiini puuduva hormooni asendamiseks või punaliblede sisalduse suurendamiseks veres.
English: The lowest dose that provides adequate control of symptoms should be used.
Estonian: Kasutada tuleb vähimat annust, millega on võimalik sümptomeid piisavalt leevendada.
English: As with other medicines containing an epoetin, the most common side effect with Retacrit is an increase in blood pressure, which can sometimes lead to symptoms of encephalopathy (brain problems) such as sudden stabbing migraine-like headache and confusion.
Estonian: Nagu teistegi epoetiini sisaldavate ravimite korral, on Retacriti kõige sagedam kõrvalnäht vererõhu tõus, mis võib mõnikord põhjustada entsefalopaatia (ajuhäirete) sümptomeid, näiteks äkki tekkivat lõikavat migreenitaolist peavalu ja segasust.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Retacrit.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: It is available in prefilled syringes containing between 1,000 and 40,000 international units (IU) of the active substance, epoetin zeta.
Estonian: Seda turustatakse eeltäidetud süstaldes, mis sisaldavad 1000-40 000 rahvusvahelist ühikut (IU) toimeainet dzeetaepoetiini.
English: Retacrit was also as effective as the reference medicine in patients with kidney problems.
Estonian: Retacrit oli sama efektiivne kui võrdlusravim ka neeruprobleemidega patsientidel.
English: Retacrit was also effective when it was injected under the skin.
Estonian: Retacrit oli efektiivne ka süstimisel naha alla.
English: Other information about Retacrit:
Estonian: Muu teave Retacriti kohta
English: In both studies, the main measures of effectiveness were the levels of haemoglobin during treatment, as well as the dose of epoetin received.
Estonian: Mõlemas uuringus oli efektiivsuse põhinäitaja vere hemoglobiinisisaldus ravi ajal, samuti saadud epoetiiniannus.
English: For patients with chronic renal failure or receiving chemotherapy, haemoglobin levels should remain within the recommended range (between 10 and 12 grams per decilitre in adults and between 9.5 and 11 g/dl in children).
Estonian: Kroonilise neerupuudulikkusega või keemiaravi saavatel patsientidel peab vere hemoglobiinisisaldus jääma soovitatavasse vahemikku (täiskasvanutel 10-12 g/dl ja lastel 9,511 g/dl).
English: This document is a summary of the European Public Assessment Report (EPAR) for Retacrit.
Estonian: Käesolev dokument on ravimi Retacrit Euroopa avaliku hindamisaruande kokkuvõte.
English: The iron levels of all patients should be checked before treatment to make sure that they are not too low, and iron supplements should be used throughout treatment.
Estonian: Enne ravi tuleb kõikidel patsientidel kontrollida, et vere rauasisaldus ei oleks liiga väike, ning kogu ravi vältel tuleb manustada täiendavaid rauapreparaate.
English: In the correction study, haemoglobin levels were around 11.6 g/dl during the last four weeks of the study, having risen from around 8.0 g/dl before treatment.
Estonian: Sisalduse parandamise uuringus oli hemoglobiinisisaldus enne ravi ligikaudu 8,0 g/dl ja uuringu viimase nelja nädala ajal ligikaudu 11,6 g/dl.
English: Therefore, the CHMP's view was that, as for Eprex/Erypo, the benefit outweighs the identified risks.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Eprexi/Erypo korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
English: It is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to produce epoetin zeta.
Estonian: Seda valmistatakse rekombinant-DNA-tehnika abil: seda toodab rakk, millele on lisatud dzeetaepoetiini teket võimaldav geen (DNA).
English: For the full list of all side effects reported with Retacrit, see the package leaflet.
Estonian: Retacriti kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The reference medicine for Retacrit is Eprex/Erypo, which contains epoetin alfa.
Estonian: Retacriti võrdlusravim on Eprex/Erypo, mis sisaldab alfaepoetiini.
English: All of the patients in the second study had been receiving treatment with Eprex/Erypo for at least three months before they were either switched to Retacrit or remained on Eprex/Erypo for 12 weeks.
Estonian: Kõikidele teise uuringu patsientidele oli manustatud vähemalt kolme kuu vältel Eprexi/Erypot, enne kui nad viidi üle ravile Retacritiga või jätkasid Eprexi/Erypo kasutamist 12 nädala jooksul.
English: The study in patients receiving chemotherapy showed that Retacrit brought about similar improvements in haemoglobin levels as those reported in the scientific literature for other epoetins.
Estonian: Keemiaravi saanud patsientide uuring näitas, et Retacrit tekitas sarnast hemoglobiinisisalduse paranemist kui teaduskirjanduse andmeil teised epoetiinid.
English: Retacrit must not be used prior to major bone surgery in patients who have a severe disease affecting their arteries or their blood vessels in the heart, neck or brain, including patients who have recently had a heart attack or stroke.
Estonian: Retacriti ei tohi kasutada enne ulatuslikku luuoperatsiooni patsientidel, kellel on südame-, kaela- või ajuveresooni ja -artereid mõjutav haigus, sealhulgas ka patsientidel, kellel on hiljuti olnud südameinfarkt või insult.
English: The company also presented the results of two studies looking at the effects of Retacrit injected under the skin: one involved 261 cancer patients receiving chemotherapy, and the other compared Retacrit with Eprex/Erypo in 462 patients with anaemia caused by kidney problems.
Estonian: Ettevõte esitas ka kahe uuringu tulemused, milles vaadeldi naha alla süstitava Retacriti toimet: ühes uuringus osales 261 keemiaravi saavat vähipatsienti ja teises võrreldi Retacriti Eprexi/Erypoga 462 neeruhäiretest põhjustatud aneemiaga patsiendil.
English: • to treat anaemia in adults receiving chemotherapy to treat certain types of cancer and to reduce the need for blood transfusions;
Estonian: • aneemia ravi teatavate vähivormide keemiaravi saavatel täiskasvanutel, et vähendada vereülekannete vajadust;
English: For patients with kidney problems, Retacrit can be injected into a vein or under the skin.
Estonian: Neeruprobleemidega patsientidele saab Retacriti süstida veeni või naha alla.
English: The active substance in Retacrit, epoetin zeta, is a copy of human erythropoietin and works in exactly the same way as the natural hormone to stimulate red blood cell production.
Estonian: Retacriti toimeaine dzeetaepoetiin on inimese erütropoetiini koopia ja toimib täpselt samamoodi kui looduslik hormoon, stimuleerides punaliblede teket.
English: In both studies, the dose of epoetin received was similar with both medicines.
Estonian: Mõlemas uuringus oli saadud epoetiiniannus sarnane.
English: Erythropoietin is also used before surgery to increase the number of red blood cells to help patients produce more blood for self-donation.
Estonian: Erütropoetiini kasutatakse ka enne operatsiooni vere punaliblede sisalduse suurendamiseks, et patsiendil tekiks autoloogseks vereülekandeks rohkem verd.
English: Treatment with Retacrit must be started under the supervision of doctors who have experience in the management of patients with the conditions that the medicine is used for.
Estonian: Ravi Retacritiga peab alustama ravimi näidustusteks olevate seisunditega patsientide ravis kogenud arsti järelevalve all.
English: It must not be used in patients who have developed pure red cell aplasia (reduced or stopped red blood cell production) following treatment with any erythropoietin, patients with hypertension (high blood pressure) that is not controlled, patients about to undergo surgery who have severe cardiovascular (heart and blood vessel) problems including a recent heart attack or stroke, or patients who cannot receive medicines to prevent blood clots.
Estonian: Ravimit ei tohi kasutada patsiendid, kellel on tekkinud pärast mis tahes erüpoetiiniga ravi isoleeritud erütrotsütaarne aplaasia (punaliblede teke on vähenenud või lakanud); patsiendid, kellel on ravile allumatu hüpertensioon (kõrgvererõhk); patsiendid, kellel on südame-veresoonkonna rasked häired, sh hiljuti olnud infarkt või insult, ja kellel on ees operatsioon; ja patsiendid, kes ei saa kasutada vere hüübimist pärssivaid ravimeid.
English: What is the risk associated with Retacrit?
Estonian: Mis riskid kaasnevad Retacritiga?
English: Retacrit should not be used in people who may be hypersensitive (allergic) to epoetin zeta or any of the other ingredients.
Estonian: Retacriti ei tohi kasutada patsiendid, kes võivad olla dzeetaepoetiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Retacrit is a ‘biosimilar' medicine.
Estonian: Retacrit on bioloogiliselt sarnane ravim.
English: Retacrit, injected into a vein, was compared with the reference medicine in two main studies involving 922 patients who had anaemia associated with chronic renal failure requiring haemodialysis (a technique for removing waste products from the blood).
Estonian: Veeni süstitavat Retacriti võrreldi võrdlusravimiga kahes põhiuuringus, milles osales 922 kroonilisest neerupuudulikkusest põhjustatud aneemiaga patsienti, kes vajasid hemodialüüsi (teatud verepuhastusmeetod).
English: In the study of patients already being treated with an epoetin, haemoglobin levels were maintained at around 11.4 g/dl when the patients were receiving Retacrit and when they were receiving Eprex/Erypo.
Estonian: Neeruhäiretest põhjustatud aneemiaga patsientide uuringus säilis vere hemoglobiinisisaldus väärtusel ligikaudu 11,4 g/dl nii patsientidel, kes said Retacriti, kui ka patsientidel, kes said Eprexi/Erypot.
English: Haemoglobin is the protein in red blood cells that carries oxygen around the body.
Estonian: Hemoglobiin on vere punaliblede valk, mis kannab hapnikku organismis laiali.
English: Why has Retacrit been approved?
Estonian: Miks Retacrit heaks kiideti?
English: The CHMP concluded that, in accordance with EU requirements, Retacrit has been shown to have a comparable quality, safety and efficacy profile to Eprex/Erypo.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Retacrit võrdväärne kvaliteet ja bioekvivalentsus ravimitega Eprex/Erypo.
English: The first study compared the effects of Retacrit with those of Eprex/Erypo in correcting red blood cell counts in 609 patients over 24 weeks.
Estonian: Esimeses uuringus võrreldi Retacriti toimet Eprexi/Erypo toimega punaliblede sisalduse parandamisel 609 patsiendil 24 nädala jooksul.
English: What is Retacrit?
Estonian: Mis on Retacrit?
English: For patients receiving chemotherapy, it must be injected under the skin, and for patients about to undergo surgery, it must be injected into a vein.
Estonian: Keemiaravi saavatele patsientidele peab ravimit süstima naha alla ning enne operatsiooni peab ravimit süstima veeni.
English: A hormone called erythropoietin stimulates the production of red blood cells from the bone marrow.
Estonian: Hormoon erütropoetiin stimuleerib vere punalibleloomet luuüdis.
English: Retacrit can also lead to skin rash and influenza (flu)-like symptoms.
Estonian: Retacrit võib põhjustada ka nahalöövet ja gripilaadseid sümptomeid.
English: The second study compared the effects of Retacrit with those of Eprex/Erypo in maintaining red blood cell counts in 313 patients.
Estonian: Teises uuringus võrreldi Retacriti toimet Eprexi/Erypo toimega punaliblede sisalduse säilitamisel 313 patsiendil.
English: Erythropoietin is produced by the kidneys.
Estonian: Erütropoetiin tekib neerudes.
English: • to reduce the need for blood transfusions in patients with moderate anaemia about to undergo major bone surgery (such as a hip or knee replacement).
Estonian: • vereülekannete vajaduse vähendamiseks mõõduka aneemiaga patsientidel enne ulatuslikku luuoperatsiooni, näiteks enne puusa-või põlveliigese asendusoperatsiooni.
English: What benefit has Retacrit shown during the studies?
Estonian: Milles seisneb uuringute põhjal Retacriti kasulikkus?
English: How is Retacrit used?
Estonian: Kuidas Retacriti kasutatakse?
English: Retacrit was as effective as Eprex/Erypo in correcting and maintaining red blood cell counts.
Estonian: Retacrit parandas ja säilitas punaliblede sisaldust veres sama efektiivselt kui Eprex/Erypo.
English: How has Retacrit been studied?
Estonian: Kuidas Retacriti uuriti?
English: What is Retacrit used for?
Estonian: Milleks Retacriti kasutatakse?
English: • to treat anaemia (low red blood cell counts) that is causing symptoms in patients with chronic renal failure (long-term, progressive decrease in the ability of the kidneys to work properly) or other kidney problems;
Estonian: • kroonilise neerupuudulikkusega (neerutalitluse pikaajaline süvenev halvenemine) või muude neeruhäiretega patsientidel sümptomeid põhjustava aneemia (punaliblede vähesus) ravi;
English: • to increase the amount of blood that patients with moderate anaemia can self-donate before surgery, so that their own blood can be given back to them during or after surgery;
Estonian: • vere hulga suurendamine mõõduka aneemiaga patsientidel, kellelt enne operatsiooni võetakse operatsiooni aegseks või -järgseks ülekandmiseks verd (autoloogne vereülekanne);
English: Retacrit is a solution for injection.
Estonian: Retacrit on retseptiravim.
English: Retacrit was studied to show that it is comparable with the reference medicine, Eprex/Erypo, in experimental models and in humans.
Estonian: Retacriti toime sarnasust võrdlusravimiga Eprex/Erypo uuriti inimuuringutes ja muude katsetega.
English: For more information about treatment with Retacrit, read the Package Leaflet (also part of the EPAR).
Estonian: Ravimi kasutamise üksikasjalik teave on pakendi infolehel, mis on samuti Euroopa avaliku hindamisaruande osa.
English: Retacrit can be injected under the skin by the patient or their carer if they have been trained appropriately.
Estonian: Kui patsient või tema hooldaja on saanud asjakohase väljaõppe, võivad nad Retacriti süstida naha alla ise.
English: How does Retacrit work?
Estonian: Kuidas Retacrit toimib?
English: A positive opinion was adopted by majority on 1 June 2006.
Estonian: 1. juunil 2006 võeti häälteenamusega vastu positiivne arvamus.
English: The Reference Member State was Germany and the Concerned Member States were Finland and the United Kingdom.
Estonian: Viiteliikmesriik oli Saksamaa ning puudutatud liikmesriikideks Soome ja Ühendkuningriik.
English: The Mutual Recognition Procedure started on 24 March 2005.
Estonian: Vastastikuse tunnustamise menetlus algas 24. märtsil 2005.
English: 1 Article 29(2) of Directive 2001/83/EC, as amended.
Estonian: 1 Direktiivi 2001/83/EÜ, koos muudatustega, artikli 29 lõige 2.
English: The Marketing Authorisation Holder provided written explanations on 28 November 2005.
Estonian: Müügiloa hoidja esitas kirjalikud selgitused 28. novembril 2005.
English: The Rapporteur was Dr. Broich and Co-Rapporteurs were Dr. Hudson and Dr. Kuitunen.
Estonian: Ettekandjaks oli dr Broich ning kaasettekandjateks dr Hudson ja dr Kuitunen.
English: The final opinion was converted into a Decision by the European Commission on 21 August 2006.
Estonian: Lõplik arvamus kinnitati Euroopa Komisjoni otsusena 21. augustil 2006.
English: This refers to the dosing recommendation for the newborn and this was considered to be of serious public health concern.
Estonian: See puudutas soovituslikku annust vastsündinutele ning seda peeti tõsiseks ohuks rahvatervisele.
English: • bacterial meningitis
Estonian: • bakteriaalne meningiit,
English: The arbitration procedure started on 15 September 2005 with the adoption of a list of questions.
Estonian: Vahekohtumenetlus algas 15. septembril 2005 küsimuste loetelu kinnitamisega.
English: Ceftriaxone is indicated for perioperative prophylaxis in patients with a certain risk of severe postoperative infections.
Estonian: Tseftriaksoon on näidustatud perioperatiivseks profülaktikaks patsientidel, kellel esineb konkreetne raskete postoperatiivsete nakkuste risk.
English: It is indicated for the treatment of the following infections when caused by micro-organisms that are susceptible to ceftriaxone and if parenteral treatment is necessary:
Estonian: See on näidustatud järgmiste infektsioonide raviks, kui need on põhjustatud tseftriaksooni suhtes tundlike mikroorganismide poolt ja vajalik on parenteraalne ravi:
English: The posology in neonates where higher doses were proposed for neonates aged 15-27 days (80 mg/kg) while the standard dose is 20-50mg/kg in the UK for neonates 0-28 days.
Estonian: 15-27 päeva vanustele vastsündinutele soovitati annust 80 mg/kg, mis on suurem kui on Ühendkuningriigis 0-28 päeva vanustele vastsündinutele manustatav normannus 20-50 mg/kg.
English: Depending on the mode of surgery and the expected spectrum of pathogens ceftriaxone should be combined with an appropriate antimicrobial agent with additional anaerobic coverage.
Estonian: Sõltuvalt operatsiooni tüübist ja patogeenide oodatavast spektrist tuleb tseftriaksooni kombineerida sobiva antimikroobse ainega, millel on laiem toime ka teistele anaeroobidele.
English: • infections of skin or soft tissues
Estonian: • naha või pehmete kudede nakkused,
English: During their May 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Ceftriaxone Tyrol Pharma and associated names, that the objections raised by United Kingdom should
Estonian: Oma 2006. aasta mai koosolekul leidis inimtervishoius kasutatavate ravimite komitee, tuginedes kõigile esitatud andmetele ja komiteesisesele teaduslikule arutelule, et Ceftriaxone Tyrol Pharma ja sarnaste nimetuste kasulikkuse ja riski vahekord on soodne ja Ühendkuningriigi poolt tõstatatud vastulaused ei saa olla müügiloa väljastamisel takistuseks ning et viiteliikmesriigi poolt esitatud ravimi
English: The United Kingdom referred the reasons for disagreement to the EMEA on 16 August 2005.
Estonian: Ühendkuningriik tegi erimeelsuste põhjuste kohta Euroopa Ravimiametile esildise 16. augustil
English: Ceftriaxone Tyrol Pharma and associated names, 1g and 2 g powder for solution for injection/infusion, is an antibiotic, being a third generation cephalosporin.
Estonian: Ceftriaxone Tyrol Pharma ja sarnaste nimetuste 1 g ja 2 g süste/infusioonilahuse pulber on antibiootikum, mis on kolmanda põlvkonna tsefalosporiin.
English: • pneumonia
Estonian: • kopsupõletik.
English: • infections of bones or joints
Estonian: • luude või liigeste nakkused,
English: The list of the product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the Summary of Product Characteristics in Annex III.
Estonian: Teaduslikud järeldused on välja toodud II lisas ning ravimi omaduste kokkuvõte III lisas.
English: not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
Estonian: omaduste kokkuvõttesse, märgistusse ja pakendi infolehte tuleb viia sisse muudatused.
English: Significant difference has been identified with regard to the proposed SPC compared to the SPC of the reference product in the UK.
Estonian: Väljapakutud ravimi omaduste kokkuvõtte ja Ühendkuningriigis turustatava võrdluspreparaadi omaduste kokkuvõtte vahel tuvastati märkimisväärne erinevus.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Ceftriaxone Tyrol Pharma and associated names International Non-Proprietary Name (INN): Ceftriaxone
Estonian: Ceftriaxone Tyrol Pharma ja sarnaste nimetuste kohta Rahvusvaheline mittekaubanduslik nimetus (INN): tseftriaksoon
English: Sandoz GmbH submitted applications for mutual recognition of Ceftriaxone Tyrol Pharma and associated names, 1g and 2g, solution for injection/infusion on the basis of the marketing authorisation granted by Germany on 13 August 2002.
Estonian: 13. augustil 2002 Saksamaa poolt väljastatud müügiloa alusel esitas Sandoz GmbH taotlused Ceftriaxone Tyrol Pharma ja sarnaste nimetuste 1 g ja 2 g süste/infusioonilahuse vastastikuseks tunnustamiseks.
English: It can be used in patients of all ages, and for short-term or long-term use.
Estonian: Seda tohivad kasutada igas vanuses patsiendid nii lühi- kui ka pikaajaliselt.
English: Patients or their carers may be able to administer Rixubis themselves at home once they have been trained appropriately.
Estonian: Patsiendid või nende hooldajad võivad Rixubist ise kodus manustada, kui nad on saanud kohase väljaõppe.
English: What measures are being taken to ensure the safe and effective use of Rixubis?
Estonian: Mis meetmed võetakse, et tagada Rixubise ohutu ja efektiivne kasutamine?
English: Other information about Rixubis
Estonian: Muu teave Rixubise kohta
English: A risk management plan has been developed to ensure that Rixubis is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Rixubise võimalikult ohutu kasutamine.
English: The full EPAR and risk management plan summary for Rixubis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Rixubise kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Rixubis on 19 December 2014.
Estonian: Euroopa Komisjon andis Rixubise müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 19 detsembril
English: Rixubis nonacog gamma
Estonian: Rixubis gammanonakog
English: What is Rixubis and what is it used for?
Estonian: Mis on Rixubis ja milleks seda kasutatakse?